NRXP vs. DARE, APRE, LEXX, SPRB, IPA, ACXP, THTX, CASI, VYNE, and ACST
Should you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Daré Bioscience (DARE), Aprea Therapeutics (APRE), Lexaria Bioscience (LEXX), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), Acurx Pharmaceuticals (ACXP), Theratechnologies (THTX), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), and Acasti Pharma (ACST). These companies are all part of the "pharmaceutical preparations" industry.
Daré Bioscience (NASDAQ:DARE) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.
In the previous week, Daré Bioscience had 7 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 9 mentions for Daré Bioscience and 2 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.10 beat Daré Bioscience's score of -0.20 indicating that Daré Bioscience is being referred to more favorably in the media.
Daré Bioscience currently has a consensus price target of $6.00, indicating a potential upside of 1,828.02%. Given NRx Pharmaceuticals' higher possible upside, equities research analysts clearly believe Daré Bioscience is more favorable than NRx Pharmaceuticals.
NRx Pharmaceuticals has lower revenue, but higher earnings than Daré Bioscience. Daré Bioscience is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Daré Bioscience's return on equity of 0.00% beat NRx Pharmaceuticals' return on equity.
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 5.3% of Daré Bioscience shares are held by insiders. Comparatively, 21.1% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Daré Bioscience received 345 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 73.18% of users gave Daré Bioscience an outperform vote.
Daré Bioscience has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Summary
Daré Bioscience beats NRx Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get NRx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NRx Pharmaceuticals Competitors List
Related Companies and Tools
